|Bid||26.00 x 800|
|Ask||34.13 x 800|
|Day's range||32.33 - 34.48|
|52-week range||27.36 - 79.45|
|Beta (5Y monthly)||1.65|
|PE ratio (TTM)||3.09|
|Earnings date||02 May 2022 - 06 May 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||60.14|
CAMBRIDGE, Mass., May 04, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will give a presentation at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 8:00am PT (11:00am ET) in Las Vegas, Nev.
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 0.96% and 66.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., May 03, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2022.